15010 Broschart Road Suite 250. 301-968-3501 We know that there are multiple aspects that inform our platform's success. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Melody Carey Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Clin Cancer Res. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies.
Home - Immunomic Therapeutics The foundation of a successful company is only as strong as the quality of its employee team. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. amy@juniper-point.com Of special note are the following publications: To browse the literature, please see the curated list at PubMed. 301-968-3501 Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. all maps fatal bullet; who is running for senate in maryland 2022 Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study.
News | Astellas Pharma Inc. Vaccine technology developed at Johns Hopkins could lead to - Hub The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. ITI-1001 GBM - pDNA. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM.
Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 Animal Health All. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. Report this profile . Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). While research is the essential engine that drives our technology forward, our efforts in process development, manufacturing management, and regulatory affairs are critical factors that advance the Immunomic Therapeutics vision. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. ITI-1000 GBM - Cell Therapy. mkemp@immunomix.com 917-322-2571, Internet Explorer presents a security risk. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent.
028300.KR | HLB Co. Ltd. Company Profile & Executives - WSJ 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. We provide a professional and challenging work environment .
Hope versus experience in glioblastoma | Evaluate It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . Contact Email info@immunic.de. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Last Funding Type Venture - Series Unknown. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI maintains its headquarters in Rockville, Maryland. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Our goal is to overcome the limitations of current immuno-oncology therapies by . SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. ITI-1001 is an alternative, cell-free approach to treating GBM. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. 717-327-1822, ITI Media: Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome.
View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Handled COVID very well.
Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates.
Immunic Therapeutics - Crunchbase Company Profile & Funding Immunomic Therapeutics Announces License Agreement With Lineage Cell Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Contact Email info@immunomet.com. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. All content is posted anonymously by employees working at Immunomic Therapeutics.
Working at Immunomic Therapeutics | Glassdoor Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. Pays for all health and welfare insurance premiums 100%. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). J Immunol Res.
Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. Operating Status Active. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates.
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Juniper Point Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Curr Opin Immunol. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Stock ticker symbol (e.g. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes.
Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Request a free trial.
Immunomic Therapeutics to Present at Biotech Showcase 2023 Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. Sia Anagnostou Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. 28 Employees .
Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Founders Sungwuk Kim. CONTACT US. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
Immunomic Therapeutics Strengthens Leadership Team with Appointment of ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company.
immunomic therapeutics crunchbase SaaS, Android, Cloud Computing, Medical Device). Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product.
CONTACT - MiNA Therapeutics | RNA Activation You will receive a reply to confirm the receipt of your application. ITI Company: immunomic therapeutics crunchbase. Description. Coordinates: 245831.9N 1213154.0E.
Immunomic Therapeutics Announces Close of $61.3M Financing The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Share this article. Headquarters Location. Active, Closed, Last funding round type (e.g. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. 1K followers 500+ connections. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent.
Pipeline - Immunomic Therapeutics ITI Media: Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with
Immunomic Therapeutics - Overview, News & Competitors | ZoomInfo.com Teri Heiland - Chief Scientific Officer (CSO) - Immunomic Therapeutics Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. Founded Date 2015. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. 917-322-2571, Internet Explorer presents a security risk.
Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC Missing the target in cancer therapy | Nature Cancer / Oct 13, 2015. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. ITI maintains its headquarters in Rockville, Maryland.
Careers - Immunomic Therapeutics aanagnostou@immunomix.com No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan.
Global Brain Cancer Market Assessment 2021-2030 - PR Newswire Great people . January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke.
New Taipei Municipal Hsin Tien Senior High School - Wikipedia Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Hershey, PA & Rockville, MD and Tokyo, Japan. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company.
Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook 15010 Broschart Dr., Suite 110, Rockville, MD 20850. For more information, please visit www.immunomix.com. ITI-1001 GBM - pDNA. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. 2015 Mar 19;519(7543):366-9.
Immunomic Therapeutics Announces First Patient Dosed in Phase I The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. Immunomic Therapeutics, Inc. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. 2017 Jun 12:1-10. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics.
Immunomic Therapeutics Inc - Company Profile and News GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Melissa Kemp This feature is in beta and may change with future updates. To demonstrate our dedication to patients and our understanding of the importance of clinical trials, we have created a . Very family oriented. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. 2006 Aug 15;177(4):2265-75.